Kaneka发布检测COVID-19变异株的PCR试剂盒

2021-10-13 国际文传 网络

该检测试剂盒能在单次PCR检测中检出四种变异株

Kaneka Corporation (TOKYO:4118)已发布KANEKA RT-PCR Kit SARS-CoV-2 (L452R/E484Q/E484K/N501Y),这是一款能同时检出COVID-19四种变异株的实时PCR检测试剂盒。该新套件建议零售价为217,800日元(含税),于9月30日开始发售。 

该检测试剂盒采用一种应用Kaneka分子检测相关技术开发的试剂。该试剂可在单次PCR检测中同时检出刺突蛋白的四种突变*1(N501Y、E484K、E484Q和L452R突变)。基于该突变检出模式,该试剂盒能高效检出变异株*2(阿尔法、德尔塔、卡帕和贝塔或伽马变异株)。 

Kaneka去年发布的检测COVID-19的PCR试剂盒于今年6月获准,名为“KANEKA Direct RT-PCR kit SARS-CoV-2”,作为体外诊断试剂使用。它广泛用于医疗机构和检测中心。通过将这款新的COVID-19变异株PCR检测试剂盒添加到williamhill asia 的产品阵容中,williamhill asia 正在为变异株快检和防止COVID-19传播做出贡献。 

Kaneka正在采取广泛的措施来抗击COVID-19。其中包括成立“感染倡议团队”,该团队研发感染(包括COVID-19)控制措施、开展DNA疫苗原料药和中间体的合同制造、供应用于“AviganTM”的原料药、开发抗体药物、供应PCR检测试剂和检测试剂盒,以及使用温控包装运送疫苗。 

*1.系指病毒刺突蛋白的氨基酸突变。上述名称基于突变。N501Y突变中,刺突蛋白的第501个氨基酸已从N(天冬酰胺)变为Y(酪氨酸)。E484K突变中,是从E(谷氨酰胺酸)变为K(赖氨酸)。E484Q中,是从E(谷氨酰胺酸)变为Q(谷氨酰胺)。L452R中,是从L(亮氨酸)变为R(精氨酸)。 

*2.被检出的COVID-19突变与变异株之间的关系(+:阳性,-:阴性) 
本产品无法区分贝塔变异株和伽马变异株。 

KANEKA RT-PCR Kit SARS-CoV-2 (L452R/E484Q/E484K/N501Y) (照片:美国商业威廉亚洲官网
)

KANEKA RT-PCR Kit SARS-CoV-2 (L452R/E484Q/E484K/N501Y) (照片:美国商业威廉亚洲官网 )

N501Y E484K E484Q L452R   定性
+ - - - ==> 阿尔法变异株
- - - + ==> 德尔塔变异株
- - + + ==> 卡帕变异株
+ + - - ==>

贝塔或伽马变异株

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1991103, encodeId=71b0199110396, content=<a href='/topic/show?id=69bd91e371a' target=_blank style='color:#2F92EE;'>#试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91737, encryptionId=69bd91e371a, topicName=试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Tue Dec 07 23:38:34 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342908, encodeId=a86e134290892, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Fri Oct 15 01:38:34 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419458, encodeId=90c6141945800, content=<a href='/topic/show?id=e290138682e' target=_blank style='color:#2F92EE;'>#PCR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13868, encryptionId=e290138682e, topicName=PCR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cc43496966, createdName=Tommy1950, createdTime=Fri Oct 15 01:38:34 CST 2021, time=2021-10-15, status=1, ipAttribution=)]
    2021-12-07 tastas
  2. [GetPortalCommentsPageByObjectIdResponse(id=1991103, encodeId=71b0199110396, content=<a href='/topic/show?id=69bd91e371a' target=_blank style='color:#2F92EE;'>#试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91737, encryptionId=69bd91e371a, topicName=试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Tue Dec 07 23:38:34 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342908, encodeId=a86e134290892, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Fri Oct 15 01:38:34 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419458, encodeId=90c6141945800, content=<a href='/topic/show?id=e290138682e' target=_blank style='color:#2F92EE;'>#PCR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13868, encryptionId=e290138682e, topicName=PCR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cc43496966, createdName=Tommy1950, createdTime=Fri Oct 15 01:38:34 CST 2021, time=2021-10-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1991103, encodeId=71b0199110396, content=<a href='/topic/show?id=69bd91e371a' target=_blank style='color:#2F92EE;'>#试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91737, encryptionId=69bd91e371a, topicName=试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Tue Dec 07 23:38:34 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342908, encodeId=a86e134290892, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Fri Oct 15 01:38:34 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419458, encodeId=90c6141945800, content=<a href='/topic/show?id=e290138682e' target=_blank style='color:#2F92EE;'>#PCR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13868, encryptionId=e290138682e, topicName=PCR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cc43496966, createdName=Tommy1950, createdTime=Fri Oct 15 01:38:34 CST 2021, time=2021-10-15, status=1, ipAttribution=)]
    2021-10-15 Tommy1950

拓展阅读

Hip Pelvis:新冠肺炎疫情对髋部骨折患者康复的影响

大流行疫情对住院护理医院的老年髋部骨折患者术后活动的恢复有不利影响,在完全限制家属进入以防止感染的情况下。

Critical Care Medicine:巴瑞替尼与c治疗重症新冠肺炎的疗效与不良反应

williamhill asia 对重症新冠肺炎住院患者进行的倾向性得分匹配的回顾性观察研究显示,与托珠单抗相比,巴瑞替尼的病死率没有差异,但不良反应显著减少。

Critical Care Medicine:肾素-血管紧张素系统途径疗法与改善新冠肺炎男性住院患者预后相关

男性使用ARB与较低的机械通气和血管活性药物的使用率有关,而在女性中没有观察到该现象。RAS系统失调的性别差异可能导致COVID-19患者预后和对ARB药物反应性的性别差异。

2023年度巨献:中国中药领域十大医学研究出炉

2023年williamhill asia 年终巨献:中国重磅级医学研究成果解读!

重磅!钟南山团队最新发表,连花清瘟的双盲、随机对照临床试验的结果出炉!

《病毒学》:与对照组相比,连花清瘟能够加速缓解多种临床症状,包括鼻塞、喉咙痛、咳嗽、发烧等等,从而促进轻至中度新冠肺炎患者的恢复。且两组安全性相当。

Lancet Respir Med:英国新冠肺炎住院后的多器官MRI发现

因新冠肺炎住院后,人们中期面临多器官异常的风险,本文发现强调了积极主动的多学科护理途径的必要性,并有可能进行成像来指导监测频率和治疗分层。